Trump Officials End a Medicare Drug Subsidy Program. How Will It Affect Costs?

The Trump administration is ending a temporary subsidy program that has helped lower Medicare Part D prescription drug costs for millions of older adults, with the decision set to take effect in 2027. CMS (Centers for Medicare & Medicaid Services) announced it would wrap up the program, which was initially implemented by the Biden administration in 2024 to counter the effects of the 2022 Inflation Reduction Act.

While federal officials claim the financial impact on beneficiaries will be minimal, the move has drawn criticism from Democrats and could potentially backfire politically ahead of a high-stakes midterm election year.

Approximately 25 million Americans with Medicare Part D plans will learn their 2027 rates in the fall when they cast their votes. Senate Minority Leader Chuck Schumer labeled the decision "heartless, cruel, and completely by choice," while CMS Administrator Mehmet Oz stated that ending the subsidy would prevent billions in taxpayer money from funneling to insurance companies.

Despite the administration's stance, most Medicare beneficiaries are expected to see an increase of less than $10 a month, with some even enjoying lower premiums.

The decision to end the subsidy program has drawn comparisons to other federal actions perceived as attacks on healthcare affordability, including Medicaid cuts and the expiration of Affordable Care Act subsidies. The federal government continues to negotiate prescription drug prices directly with pharmaceutical companies, but the current change does not affect the out-of-pocket cap for Medicare drug coverage, which stands at $2,100 in 2026 and is projected to rise to $2,400 in 2027.

The impact of the change remains uncertain, with some experts predicting marginal price increases for some consumers but potential challenges for others in the context of rising costs in other essential areas.